When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anitocabtagene autoleucel (anito-cel) which is being prepared for a filing and potential ...

Please provide your email address to receive an email when new articles are posted on . Study investigators reported limited high-grade treatment-related CRS or neurotoxicity. More than half of study ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary data ...

ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...